Contrive Datum Insights has published "In Vitro Fertilization Ivf Market Size, Share & Industry Analysis, By Type (Intrauterine Insemination, Intracytoplasmic Sperm Injection, IVF Using Donor Eggs), Devices (Imaging Systems, Sperm Separation System, Ovum Aspiration Pump, Micromanipulator, Cryosystem), Reagents (Embryo Culture Media, Cryopreservation Media, Sperm Processing Media, Ovum Processing Media), End-user (Fertility Clinics, Hospitals, Clinical Research Centers), Age group (Under 35 Years, 35 to 40 Years, Above 40 Years), and Regional Forecast, 2026-2034". The study sizes the global in vitro fertilization ivf market at USD 30 billion in 2025 and projects growth from USD 32.1 billion in 2026 to USD 55.14 billion by 2034, a compound annual growth rate of 6.99% across the forecast period.
In vitro fertilization is an assisted reproductive procedure in which eggs are retrieved from the ovaries and fertilized with sperm outside the body, with the resulting embryo transferred to the uterus; the category covers the instruments, culture media and cryopreservation systems used at each stage of the procedure alongside intrauterine insemination and donor-egg variants performed under the same clinical protocol. Buyers are fertility clinics, hospital reproductive medicine units and clinical research centers that purchase imaging, aspiration, micromanipulation and cryostorage equipment together with the consumable media each cycle requires.
Rising infertility prevalence tied to delayed childbearing
Rising infertility prevalence tied to delayed childbearing is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.99% a year, the type lines exposed to it move fastest: IVF Using Donor Eggs compounds at 10.99%, taking its share of revenue from 15% to 21% and its value from USD 4.5 billion to USD 11.58 billion.
On the upside, the study's bull case assumes faster expansion of insurance and employer fertility-benefit mandates, combined with quicker adoption of frozen embryo transfer as the default protocol, pulls cycle volume growth above the base case, which would take 2034 revenue to USD 66.78 billion against the USD 55.14 billion base case.
The downside is specific. Slower rollout of insurance mandates and continued high out-of-pocket cost in price-sensitive markets keep cycle volume growth below the base case, particularly across Latin America and parts of Asia Pacific, and 2034 revenue lands at USD 44.58 billion. Intracytoplasmic Sperm Injection is the drag, 55% of the 2025 base compounding at 6.33% while the market runs at 6.99%.
Intracytoplasmic Sperm Injection Scale Against IVF Using Donor Eggs Momentum
Suppliers here are separated by type, not by geography. The incumbent position is Intracytoplasmic Sperm Injection: 55% of 2025 revenue, USD 16.5 billion, and still 52% in 2034. The contested position is IVF Using Donor Eggs at 10.99% growth. Few suppliers hold both, which is why a market of USD 30 billion supports as many participants as it does.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Intracytoplasmic Sperm Injection | 55% · USD 16.5 billion | — |
| Devices | Imaging Systems | 30% · USD 9 billion | Cryosystem 11.64% |
| Reagents | Embryo Culture Media | 45% · USD 13.5 billion | Cryopreservation Media 8.77% |
| End-user | Fertility Clinics | 68% · USD 20.4 billion | — |
| Age group | Under 35 Years | 40% · USD 12 billion | Above 40 Years 9.46% |
- North America was the largest region in 2025, holding 32% of global revenue at USD 9.6 billion and reaching USD 15.99 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 30% in 2025 to 34.01% in 2034, with revenue growing from USD 9 billion to USD 18.75 billion.
- Middle East and Africa stays the smallest contributor across the period: 6% of revenue in 2025 and 6% in 2034.
- IVF Using Donor Eggs is projected to grow at 10.99% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 7.87 billion in 2025, 26.23% of global revenue.
The study covers five axes, by type, and by devices, reagents, end-user and age group, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 44.58 billion and USD 66.78 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.